Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASN 002 - Ascend Biopharmaceuticals

X
Drug Profile

ASN 002 - Ascend Biopharmaceuticals

Alternative Names: Ad-IFNγ; Adenovirus interferon gamma; ASN-002 - Ascend; SP-002 - Stamford Pharmaceuticals; TG-1042

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell nevus syndrome; Cutaneous T-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Basal cell cancer
  • No development reported Malignant melanoma
  • Discontinued Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma

Most Recent Events

  • 09 Apr 2024 Phase-II clinical trials in Basal cell cancer (Combination therapy, Late-stage disease) in USA (Intratumoural) (NCT06344052)
  • 14 Feb 2024 Ascend Biopharmaceuticals completes phase-IIa trial in Basal cell cancer (Combination therapy, First-line therapy) in Australia (Intratumoural) (NCT04416516)
  • 26 Sep 2022 Phase-II development is still ongoing for Basal cell cancer (Combination therapy, First-line therapy) in Australia (Intratumoural) (NCT04416516)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top